Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

oprelvekin

A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death. This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:adipogenesis inhibitory factor
IL-11
interleukin 11
recombinant human interleukin-11
therapeutic interleukin-11
US brand name:Neumega
Foreign brand name:Baijieyi
Abbreviation:rhIL-11
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search